Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
2.
Transfus Apher Sci ; 63(4): 103965, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38986352

ABSTRACT

Blood transfusion is a critical life-saving medical intervention, but it carries the risk of transfusion-transmitted infections (TTIs) that can lead to serious consequences. TTIs include viral, bacterial, parasitic, and prion infections, transmitted through asymptomatic donor blood, contamination of stored blood products, or transfusion-related immunosuppression. Recognized global agents posing challenges to blood safety include human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), Syphilis, etc. Emerging pathogens like SARS-CoV-2, hepatitis E, and others present additional risks. The residual risk of TTIs, representing the likelihood of infected donations passing screening tests, varies globally. High-income countries generally show lower prevalence rates than low-income countries. In Egypt, the estimated prevalence rates for HIV, HBV, HCV, and syphilis markers among the donors are 0.23 %, 0.76 %, 2.33 %, and 0.24 %, respectively. In Egypt, specific residual risk estimates are scarce, but prevalence rates for key infections highlight existing challenges. The World Health Organization promotes a global blood safety strategy, advocating for national blood systems, voluntary non-remunerated donors, and quality-assured testing. Despite these measures, the establishment of a haemovigilance system which is critical for monitoring and preventing adverse events, including TTIs, is reported as lacking in Egypt. This highlights the importance of comprehensive surveillance and safety measures in the blood donation process to ensure universal access to safe blood. Primary health care can play a pivotal role in preventing TTIs.


Subject(s)
Transfusion Reaction , Humans , Egypt/epidemiology , Transfusion Reaction/epidemiology , Transfusion Reaction/prevention & control , Blood Safety , Blood Transfusion/methods , Blood-Borne Infections/prevention & control , Blood-Borne Infections/epidemiology , Blood-Borne Infections/transmission , Blood Donors
4.
BMJ ; 385: q1179, 2024 06 05.
Article in English | MEDLINE | ID: mdl-38839090
7.
Nutrients ; 14(2)2022 Jan 07.
Article in English | MEDLINE | ID: mdl-35057424

ABSTRACT

Elucidating the mechanisms of bacterial translocation is crucial for the prevention and treatment of neonatal sepsis. In the present study, we aimed to evaluate the potential of lactoferrin to inhibit the development of late-onset blood infection in neonates. Our investigation evaluates the role of key stress factors leading to the translocation of intestinal bacteria into the bloodstream and, consequently, the development of life-threatening sepsis. Three stress factors, namely weaning, intraperitoneal administration of Gram-positive cocci and oral intake of Gram-negative rods, were found to act synergistically. We developed a novel model of rat pups sepsis induced by bacterial translocation and observed the inhibition of this process by supplementation of various forms of lactoferrin: iron-depleted (apolactoferrin), iron-saturated (hololactoferrin) and manganese-saturated lactoferrin. Additionally, lactoferrin saturated with manganese significantly increases the Lactobacillus bacterial population, which contributes to the fortification of the intestinal barrier and inhibits the translocation phenomenon. The acquired knowledge can be used to limit the development of sepsis in newborns in hospital neonatal intensive care units.


Subject(s)
Bacterial Translocation/drug effects , Escherichia coli , Gastrointestinal Microbiome/drug effects , Lactoferrin/administration & dosage , Neonatal Sepsis/prevention & control , Staphylococcus haemolyticus , Animals , Animals, Newborn , Apoproteins/administration & dosage , Blood-Borne Infections/microbiology , Blood-Borne Infections/prevention & control , Body Temperature , Body Weight , Cross Infection/prevention & control , Disease Models, Animal , Drug Administration Schedule , Escherichia coli/drug effects , Escherichia coli/physiology , Gastrointestinal Microbiome/physiology , Humans , Infant, Newborn , Male , Manganese/administration & dosage , Neonatal Sepsis/diagnosis , Neonatal Sepsis/microbiology , Permeability , Random Allocation , Rats , Rats, Wistar , Staphylococcus haemolyticus/drug effects , Staphylococcus haemolyticus/physiology , Weaning
8.
Ann Agric Environ Med ; 28(3): 469-474, 2021 Sep 16.
Article in English | MEDLINE | ID: mdl-34558272

ABSTRACT

INTRODUCTION: The article presents the diagnosis of the problem of blood-borne infections in Poland from perspectives of experts' opinions at the voivodship level. The evaluation became the basis for subsequent analysis, aimed at creating assumptions for the proposed strategies to prevent blood-borne infections in Poland. MATERIAL AND METHODS: Diagnosis was based on the expertise of practitioners in epidemiology and service providers. Analysis covered assessment of service safety, examples, recommended practices, forms and scope of education. Also covered is information for the general public from different aspects: points of view of recipients and service providers, legislation, system organization, and finances. The SWOT method was used in analysis. The opportunities and threats concerning the risk of blood-borne diseases for the service sector are presented, as well as data gathered from 42 representative experts from across Poland. RESULTS: Databases on health indicators, covered by the reporting obligation of all diagnosed cases, are a crucial element of the surveillance system in public health (e.g. sentinel). Additional information on health care management (risk management) is not a common and routine approach. The study fills a gap in knowledge about risk management in the medical and non-medical services sector. The information also enriches education programmes (e.g. http://www.hcv.pzh.gov.pl/). CONCLUSIONS: Currently, the evidence-based approaches in medicine and in public health are standard. Experts emphasize that the opportunities for the prevention of infection risk are linked to technological advances and innovations, while threats are seen in both financial and organizational constraints, and the non-normalized, dynamically developing service market.


Subject(s)
Blood-Borne Infections/epidemiology , Public Health , Blood-Borne Infections/diagnosis , Blood-Borne Infections/prevention & control , Humans , Poland/epidemiology , Qualitative Research , Risk Factors
9.
Transfus Apher Sci ; 60(4): 103207, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34353706

ABSTRACT

Blood transfusions come with risks and high costs, and should be utilized only when clinically indicated. Decisions to transfuse are however not always well informed, and lack of clinician knowledge and education on good clinical transfusion practices contribute to the inappropriate use of blood. Low and middle-income countries in particular take much strain in their efforts to address blood safety challenges, demand-supply imbalances, high blood costs as well as high disease burdens, all of which impact blood usage and blood collections. Patient blood management (PBM), which is a patient-focused approach aimed at improving patient outcomes by preemptively diagnosing and correcting anaemia and limiting blood loss by cell salvage, coagulation optimization and other measures, has become a major approach to addressing many of the challenges mentioned. The associated decrease in the use of blood and blood products may be perceived as being in competition with blood conservation measures, which is the more traditional, but primarily product-focused approach. In this article, we hope to convey the message that PBM and blood conservation should not be seen as competing concepts, but rather complimentary strategies with the common goal of improving patient care. This offers opportunity to improve the culture of transfusion practices with relief to blood establishments and clinical services, not only in South Africa and LMICs, but everywhere. With the COVID-19 pandemic impacting blood supplies worldwide, this is an ideal time to call for educational interventions and awareness as an active strategy to improve transfusion practices, immediately and beyond.


Subject(s)
Blood Banks/organization & administration , Blood Transfusion , Bloodless Medical and Surgical Procedures , Anemia/therapy , Blood Banks/economics , Blood Loss, Surgical , Blood Safety , Blood Transfusion/economics , Blood-Borne Infections/prevention & control , Bloodless Medical and Surgical Procedures/economics , COVID-19 , Clinical Decision-Making , Developing Countries , Donor Selection/economics , Evidence-Based Medicine , Female , HIV Infections/epidemiology , HIV Infections/prevention & control , Health Services Needs and Demand , Humans , Male , Pandemics , Postpartum Hemorrhage/therapy , Practice Guidelines as Topic , Pregnancy , Prevalence , Procedures and Techniques Utilization , SARS-CoV-2 , South Africa/epidemiology , Transfusion Medicine/education
11.
J Infect Dev Ctries ; 15(6): 847-852, 2021 06 30.
Article in English | MEDLINE | ID: mdl-34242196

ABSTRACT

INTRODUCTION: Our aim was to evaluate a screening program, with active case-finding and treatment for active tuberculosis (TB), latent tuberculosis infection (LTBI), blood-borne viruses (BBV), and sexually transmitted diseases (STDs) among refugees living in facility centers. METHODOLOGY: We collected data on refugees arriving to our attention in migrant centers in Sardinia, Italy. Socio-demographical data, anamnesis, and clinical features were collected. TST Mantoux was conducted, and X-ray chest (XRC) was performed if TST was positive. Blood-borne virus screening was proposed to all patients. Screening for STDs was offered according to guidelines, anamnesis, and physical examination. RESULTS: Eighty-one patients were included. Seventy (86.4%) were male, and the mean age was 24.8±5.7 years. Thirty-three (40.7%) had scabies. Overall, 40/81 (49.4%) had a positive TST Mantoux. One (2.5%) was hospitalized and died for multi-drug-resistant TB. One (2.5%) patient had intestinal-TB. 52/81 (64.2%) refused HIV screening, whereas no positivity was found among tested migrants. Sixty-two (76.5%) accepted HCV screening, and one (1.6%) had a positive test. Fifty-eight (71.6%%) accepted HBV testing, and 29 (50%) of them had positive serology. Ten (12.3%) patients had anal or genital lesions due to syphilis, Molluscum contagiosum, and HPV in 7 (70%), 2 (20%), and one (10%) case, respectively. CONCLUSIONS: Infectious diseases control and prevention are a key strategy among refugees. The stay in a migrant center is an extraordinary occasion for healthcare provision. This condition could allow a broad screening program in which quick BBV screening tests could be a good method to implement uptake. More information and educational programs would allow a higher understanding and acceptance of HIV screening.


Subject(s)
Communicable Diseases/epidemiology , Mass Screening , Refugees , Blood-Borne Infections/diagnosis , Blood-Borne Infections/epidemiology , Blood-Borne Infections/prevention & control , Communicable Disease Control , Communicable Diseases/diagnosis , Demography , Female , Humans , Italy/epidemiology , Latent Tuberculosis/diagnosis , Latent Tuberculosis/epidemiology , Latent Tuberculosis/prevention & control , Male , Nigeria/ethnology , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/prevention & control , Socioeconomic Factors , Surveys and Questionnaires , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/prevention & control , Young Adult
12.
Transfus Apher Sci ; 60(4): 103154, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33994107

ABSTRACT

BACKGROUND: Convalescent plasma (CP) has been used in the past in various pandemics, in particular in H1N1, SARS and MERS infections. In Spring 2020, when ongoing the SARS-CoV-2 pandemics, the Veneto Region (V-R) has proposed setting-up an anti-SARS-CoV-2 CP (CCP) Bank, with the aim of preparing a supply of CCP immediately available in case of subsequest epidemic waves. MATERIALS AND METHODS: Key-points to be developed for a quick set-up of the V-R CCP Bank have been recruitment of donors recovered from COVID-19 infection, laboratory analysis for the biological qualification of the CCP units, including titre of neutralizing antibodies and reduction of pathogens, according to National Blood Centre (CNS) Directives, adaptation of the V-R Information Technology systems and cost analysis. Some activities, including diagnostic and viral inactivation processes, have been centralized in 2 or 3 sites. Laboratory analysis upon preliminary admission of the donor included all tests required by the Italian laws and the CNS directives. RESULTS: From April to August 2020, 3,298 people have contacted the V-R Blood Transfusion Services: of these, 1,632 have been evaluated and examined as first time donors and those found to be suitable have carried out 955 donations, from which 2,626 therapeutic fractions have been obtained, at a cost around 215,00 Euro. Since October 2020, the number of COVID-19 inpatients has had a surge with a heavy hospital overload. Moreover, the high request of CCP therapy by clinicians has been just as unexpected, showing a wide therapeutic use. CONCLUSIONS: The organizational model here presented, which has allowed the rapid collection of a large amount of CCP, could be useful when facing new pandemic outbreaks, especially in low and middle income countries, with generally acceptable costs.


Subject(s)
Blood Banks/organization & administration , COVID-19/therapy , Civil Defense/organization & administration , Pandemics , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Blood Banks/economics , Blood Donors , Blood Safety/methods , Blood-Borne Infections/prevention & control , Costs and Cost Analysis , Donor Selection/legislation & jurisprudence , Humans , Immunization, Passive/statistics & numerical data , Italy , Models, Organizational , Plasma , SARS-CoV-2/immunology , Virus Inactivation , COVID-19 Serotherapy
13.
Br J Haematol ; 195(2): 174-185, 2021 10.
Article in English | MEDLINE | ID: mdl-33955555

ABSTRACT

The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.


Subject(s)
Blood-Borne Infections/prevention & control , HIV Infections/prevention & control , Hemophilia A/therapy , Hepatitis, Viral, Human/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Antiviral Agents/therapeutic use , Blood Coagulation Factors/therapeutic use , Blood-Borne Infections/etiology , Blood-Borne Infections/transmission , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/epidemiology , Disease Management , HIV/isolation & purification , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/transmission , Hemophilia A/complications , Hemophilia A/epidemiology , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/drug therapy , Hepatitis, Viral, Human/transmission , Humans , Liver Neoplasms/pathology , Liver Transplantation/adverse effects , Middle Aged , Morbidity/trends , Mortality/trends , Persistent Infection , Vaccination/methods , Young Adult
14.
Transfus Apher Sci ; 60(4): 103129, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33879420

ABSTRACT

Call back as a procedure to report post donation symptoms or illness by donors has been established since 2009 in Iranian Blood Transfusion Organization (IBTO). During the first phase of COVID-19 outbreak, all blood donors were requested to report any respiratory infection symptoms after donation. The study investigated the callback data of COVID-19 in Tehran Blood Center during the first 3 months of the outbreak in Iran. The purpose of this study was to estimate the frequency of post donation COVID-19 related call back reports and determine its implications for blood donors and patients. A telephone interview was conducted with donors who had reported COVID-19 symptoms. Some questions were asked to evaluate donor's health at the time of blood donation. The donors categorized into three groups: laboratory-confirmed, suspected, and COVID-19 irrelevant based on their answers. In cases that the blood component obtained from a laboratory-confirmed donor had been released, the hospital was notified and asked to follow up the recipient for COVID-19. The results showed 30 donors (0.08 %) had callback related to COVID-19 and 76.63 % of the obtained component was disposed. The results also showed that only one donor had a laboratory-confirmed result with the RBC unit processed from her whole blood released for transfusion. The RBC unit recipient did not show any signs or symptoms of infection during a 46-day follow-up. Concluded that callback system was effective to remove most of the components obtained from the donors who reported to be COVID-19 suspected or confirmed. Moreover, the result did not support virus transmission through blood transfusion.


Subject(s)
Blood Donors , Blood Safety , Blood-Borne Infections/prevention & control , COVID-19/prevention & control , Donor Selection , Pandemics , SARS-CoV-2 , Transfusion Reaction/prevention & control , Adult , Aged , Blood Component Transfusion/adverse effects , Blood Component Transfusion/statistics & numerical data , COVID-19/blood , COVID-19/diagnosis , COVID-19/transmission , COVID-19 Nucleic Acid Testing , Erythrocyte Transfusion/adverse effects , Female , Follow-Up Studies , Humans , Infant, Newborn , Interviews as Topic , Iran/epidemiology , Male , Middle Aged , Pulmonary Valve Stenosis/surgery , Symptom Assessment , Young Adult
15.
Cochrane Database Syst Rev ; 4: CD012060, 2021 Apr 14.
Article in English | MEDLINE | ID: mdl-33871067

ABSTRACT

BACKGROUND: In healthcare settings, health care workers (HCWs) are at risk of acquiring infectious diseases through sharps injuries and splash exposures to blood or bodily fluids. Education and training interventions are widely used to protect workers' health and safety and to prevent sharps injuries. In certain countries, they are part of obligatory professional development for HCWs. OBJECTIVES: To assess the effects of education and training interventions compared to no intervention or alternative interventions for preventing sharps injuries and splash exposures in HCWs. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, NHSEED, Science Citation Index Expanded, CINAHL and OSH-update (from all time until February 2016). In addition, we searched the databases of Global Health, AustHealth and Web of Science (from all time until February 2016). The original search strategy was re-run in November 2019, and again in February 2020. In April 2020, the search strategy was updated and run in CINAHL, MEDLINE, Scopus and Web of Science (from 2016 to current). SELECTION CRITERIA: We considered randomized controlled trials (RCTs), cluster-randomized trials (cluster-RCTs), controlled clinical trials (CCTs), interrupted time series (ITS) study designs, and controlled before-and-after studies (CBA), that evaluated the effect of education and training interventions on the incidence of sharps injuries and splash exposures compared to no-intervention. DATA COLLECTION AND ANALYSIS: Two authors (SC, HL) independently selected studies, and extracted data for the included studies. Studies were analyzed, risk of bias assessed (HL, JL) , and pooled using random-effect meta-analysis, where applicable, according to their design types. As primary outcome we looked for sharps injuries and splash exposures and calculated them as incidence of injuries per 1000 health care workers per year. For the quality of evidence we applied GRADE for the main outcomes. MAIN RESULTS: Seven studies met our inclusion criteria: one cluster-RCT, three CCTs, and three ITS studies. The baseline rates of sharps injuries varied from 43 to 203 injuries per 1000 HCWs per year in studies with hospital registry systems. In questionnaire-based studies, the rates of sharps injuries were higher, from 1800 to 7000 injuries per 1000 HCWs per year.  The majority of studies utilised a combination of education and training interventions, including interactive demonstrations, educational presentations, web-based information systems, and marketing tools which we found similar enough to be combined. In the only cluster-RCT (n=796) from a high-income country, the single session educational workshop decreased sharps injuries at 12 months follow-up, but this was not statistically significant either measured as registry-based reporting of injuries (RR 0.46, 95% CI 0.16 to 1.30, low-quality evidence) or as self-reported injuries (RR 0.41, 95% CI 0.14 to 1.21, very low-quality evidence) In three CCTs educational interventions decreased sharps injuries at two months follow-up (RR 0.68, 95% CI 0.48 to 0.95, 330 participants, very low-quality evidence). In the meta-analysis of two ITS studies with a similar injury rate, (N=2104), the injury rate decreased immediately post-intervention by 9.3 injuries per 1000 HCWs per year (95% CI -14.9 to -3.8). There was a small non-significant decrease in trend over time post-intervention of 2.3 injuries per 1000 HCWs per year (95% CI -12.4 to 7.8, low-quality evidence). One ITS study (n=255) had a seven-fold higher injury rate compared to the other two ITS studies and only three data points before and after the intervention. The study reported a change in injury rate of 77 injuries per 1000 HCWs (95% CI -117.2 to -37.1, very low-quality evidence) immediately after the intervention, and a decrease in trend post-intervention of 32.5 injuries per 1000 HCWs per year (95% CI -49.6 to -15.4, very low quality evidence). None of the studies allowed analyses of splash exposures separately from sharps injuries. None of the studies reported rates of blood-borne infections in patients or staff. There was very low-quality evidence of short-term positive changes in process outcomes such as knowledge in sharps injuries and behaviors related to injury prevention.  AUTHORS' CONCLUSIONS: We found low- to very low-quality evidence that education and training interventions may cause small decreases in the incidence of sharps injuries two to twelve months after the intervention. There was very low-quality evidence that educational interventions may improve knowledge and behaviors related to sharps injuries in the short term but we are uncertain of this effect. Future studies should focus on developing valid measures of sharps injuries for reliable monitoring. Developing educational interventions in high-risk settings is another priority.


Subject(s)
Blood-Borne Infections/prevention & control , Health Personnel/education , Occupational Exposure/prevention & control , Wounds, Stab/prevention & control , Controlled Before-After Studies , Controlled Clinical Trials as Topic , Humans , Interrupted Time Series Analysis , Needlestick Injuries/epidemiology , Needlestick Injuries/prevention & control , Randomized Controlled Trials as Topic , Wounds, Stab/epidemiology
16.
Epidemiol Infect ; 149: e59, 2021 01 25.
Article in English | MEDLINE | ID: mdl-33487201

ABSTRACT

People in prison are disproportionately affected by viral hepatitis. To examine the current epidemiology of and responses targeting hepatitis B virus (HBV) in prisons across the European Union, European Economic Area and United Kingdom, we analysed HBV-specific data from the World Health Organization's Health in Prisons European Database and the European Centre for Disease Prevention and Control's hepatitis B prevalence database. Hepatitis B surface antigen seroprevalence ranged from 0% in a maximum-security prison in United Kingdom to 25.2% in two Bulgarian juvenile detention centres. Universal HBV screening on opt-out basis and vaccination were reported available in 31% and 85% of 25 countries, respectively. Disinfectants, condoms and lubricants were offered free of charge in all prisons in the country by 26%, 46% and 15% of 26 countries, respectively. In 38% of reporting countries, unsupervised partner visits with the possibility for sexual intercourse was available in all prisons. The findings are suggestive of high HBV prevalence amidst suboptimal coverage of interventions in prisons. A harmonised monitoring system and robust data at national and regional levels are needed to better understand the HBV situation in prisons within the framework of the European action plan and Global Health Sector Strategy on viral hepatitis.


Subject(s)
European Union , Hepatitis B/epidemiology , Prisons , Blood-Borne Infections/prevention & control , Blood-Borne Infections/virology , Diagnostic Screening Programs , Europe/epidemiology , Female , Humans , Male , Scandinavian and Nordic Countries/epidemiology , Sexually Transmitted Diseases/prevention & control , United Kingdom/epidemiology
17.
Epidemiol Rev ; 42(1): 4-18, 2020 01 31.
Article in English | MEDLINE | ID: mdl-33024995

ABSTRACT

Preventing the transition to injection drug use is an important public health goal, as people who inject drugs (PWID) are at high risk for overdose and acquisition of infectious disease. Initiation into drug injection is primarily a social process, often involving PWID assistance. A better understanding of the epidemiology of this phenomenon would inform interventions to prevent injection initiation and to enhance safety when assistance is provided. We conducted a systematic review of the literature to 1) characterize the prevalence of receiving (among injection-naive persons) and providing (among PWID) help or guidance with the first drug injection and 2) identify correlates associated with these behaviors. Correlates were organized as substance use behaviors, health outcomes (e.g., human immunodeficiency virus infection), or factors describing an individual's social, economic, policy, or physical environment, defined by means of Rhodes' risk environments framework. After screening of 1,164 abstracts, 57 studies were included. The prevalence of receiving assistance with injection initiation (help or guidance at the first injection) ranged 74% to 100% (n = 13 estimates). The prevalence of ever providing assistance with injection initiation varied widely (range, 13%-69%; n = 13 estimates). Injecting norms, sex/gender, and other correlates classified within Rhodes' social risk environment were commonly associated with providing and receiving assistance. Nearly all PWID receive guidance about injecting for the first time, whereas fewer PWID report providing assistance. Substantial clinical and statistical heterogeneity between studies precluded meta-analysis, and thus local-level estimates may be necessary to guide the implementation of future psychosocial and sociostructural interventions. Further, estimates of providing assistance may be downwardly biased because of social desirability factors.


Subject(s)
Administration, Intravenous , Helping Behavior , Blood-Borne Infections/prevention & control , Humans , Mortality , Prevalence
18.
Blood Transfus ; 18(6): 454-464, 2020 11.
Article in English | MEDLINE | ID: mdl-33000752

ABSTRACT

BACKGROUND: As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo. MATERIALS AND METHODS: Whole blood (WB)- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT® Blood System (Cerus Corporation, Concord, CA, USA) and cryo was prepared from treated plasma. Protein levels in PI-cryo and paired controls were quantified using liquid chromatography-tandem mass spectrometry. Functional haemostatic properties of PI-cryo were assessed using a microparticle (MP) prothrombinase assay, thrombin generation assay, and an in vitro coagulopathy model subjected to thromboelastometry. RESULTS: Over 300 proteins were quantified across paired PI-cryo and controls. PI did not alter the expression of coagulation factors, but levels of platelet-derived proteins and platelet-derived MPs were markedly lower in the WB PI-cryo group. Compared to controls, WB (but not APH) cryo samples demonstrated significantly lower MP prothrombinase activity, prolonged clotting time, and lower clot firmness on thromboelastometry after PI. However, PI did not affect overall thrombin generation variables in either group. DISCUSSION: Data from this study suggest that PI via INTERCEPT® Blood System does not significantly impact the coagulation factor content or function of cryo but reduces the higher MP content in WB-derived cryo. PI-cryo products may confer benefits in reducing pathogen transmission without affecting haemostatic function, but further in vivo assessment is warranted.


Subject(s)
Blood Proteins/drug effects , Blood Proteins/radiation effects , Blood Safety , Blood-Borne Infections/prevention & control , Blood-Borne Pathogens/drug effects , Blood-Borne Pathogens/radiation effects , Microbial Viability , Plasma/drug effects , Plasma/radiation effects , Virus Inactivation , Blood Component Removal , Blood Platelets/chemistry , Blood Preservation , Blood Proteins/analysis , Cell-Derived Microparticles/enzymology , Cryopreservation , Furocoumarins/pharmacology , Furocoumarins/radiation effects , Humans , Microbial Viability/drug effects , Microbial Viability/radiation effects , Photochemistry , Photosensitizing Agents/pharmacology , Photosensitizing Agents/radiation effects , Plasma/microbiology , Plasma/virology , Thrombelastography , Thrombin/biosynthesis , Thromboplastin/analysis , Ultraviolet Rays , Virus Inactivation/drug effects , Virus Inactivation/radiation effects
19.
Transfusion ; 60(9): 1987-1997, 2020 09.
Article in English | MEDLINE | ID: mdl-32743798

ABSTRACT

Risk assessments of transfusion-transmitted emerging infectious diseases (EIDs) are complicated by the fact that blood donors' demographics and behaviors can be different from the general population. Therefore, when assessing potential blood donor exposure to EIDs, the use of general population characteristics, such as U.S. travel statistics, may invoke uncertainties that result in inaccurate estimates of blood donor exposure. This may, in turn, lead to the creation of donor deferral policies that do not match actual risk. STUDY DESIGN AND METHODS: This article reports on the development of a system to rapidly assess EID risks for a nationally representative portion of the U.S. blood donor population. To assess the effectiveness of this system, a test survey was developed and deployed to a statistically representative sample frame of blood donors from five blood collecting organizations. Donors were directed to an online survey to ascertain their recent travel and potential exposure to Middle East respiratory syndrome coronavirus (MERS-CoV). RESULTS: A total of 7128 responses were received from 54 256 invitations. The age-adjusted estimated total number of blood donors potentially exposed to MERS-CoV was approximately 15 640 blood donors compared to a lower U.S. general population-based estimate of 9610 blood donors. CONCLUSION: The structured donor demographic sample-based data provided an assessment of blood donors' potential exposure to an emerging pathogen that was 63% larger than the U.S. population-based estimate. This illustrates the need for tailored blood donor-based EID risk assessments that provide more specific demographic risk intelligence and can inform appropriate regulatory decision making.


Subject(s)
Blood Donors , Blood Transfusion , Blood-Borne Infections/epidemiology , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Imported/epidemiology , Coronavirus Infections/epidemiology , Environmental Exposure , Risk Assessment/methods , Surveys and Questionnaires , Travel-Related Illness , Adolescent , Adult , Aged , Aged, 80 and over , Blood Banks , Blood Donors/statistics & numerical data , Blood-Borne Infections/blood , Blood-Borne Infections/prevention & control , Blood-Borne Infections/transmission , Communicable Diseases, Emerging/blood , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/transmission , Communicable Diseases, Imported/blood , Communicable Diseases, Imported/prevention & control , Communicable Diseases, Imported/transmission , Coronavirus Infections/blood , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Decision Making , Female , Humans , Male , Middle Aged , Middle East , Middle East Respiratory Syndrome Coronavirus , Sample Size , Sampling Studies , Transfusion Reaction/prevention & control , United States/epidemiology , Young Adult
20.
Vox Sang ; 115(8): 637-646, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32702174

ABSTRACT

BACKGROUND AND OBJECTIVES: Injecting drug use (IDU), a permanent deferral for blood donors, was included in a review of donor selection criteria completed in 2017. Here, we describe what is known about IDU in blood donors in the United Kingdom (UK). MATERIALS AND METHODS: Data were obtained from routine surveillance of donation testing and confirmed positive donors and a 2013/2014 UK survey of behaviour and compliance in screen-negative donors. RESULTS: Between 2009 and 2018, of 22 UK million donations screened, IDU was self-reported at the post-test discussion in 5% (86/1777) of donors with confirmed positive donations. Recent injecting within 12 months was reported in 8 HCV-positive donors, but only in 1/14 donors where it was clear HCV infection had been acquired in the previous 12 months. Of 65 439 survey responders, 25 reported IDU, which when weighted to the donor population gave 99·95% compliance. Most of the 111 donors reporting IDU felt it was not important to their donation, mainly because their injecting was in the past, while three HCV-positive recent injectors reported not sharing needles so presumably felt safe to donate. CONCLUSION: Compliance with the permanent deferral appeared extremely high with low levels of injecting reported by donors, mainly in the past. This agreed with the low-incident HCV infection observed in UK donors. These data contributed to a recommendation to reduce the deferral to 1 year. Ways of improving compliance in those few donors at current increased risk of infection need to be investigated.


Subject(s)
Blood Donors , Blood-Borne Infections/prevention & control , Donor Selection , Drug Users , Adolescent , Adult , Blood-Borne Infections/epidemiology , Female , Hepatitis C/epidemiology , Humans , Injections , Male , Middle Aged , Patient Compliance , United Kingdom/epidemiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL